AML FISH Panel expanded for more clinical information

Effective February 1, 2016, the Applied Diagnostics' AML FISH Panel will include 3 additional tests to provide improved prognostic assessment for patients.  The new tests are:  1) Deletion 5q/monosomy 5,  2)  Deletion 7q/monosomy 7, and 3) CEN 7.

No change in ordering is required.  Please see the Test Directory for more information on probes and revised CPT Codes.  


 

"Revolutionary time in multiple myeloma"

New drugs mean more than 80% of newly diagnosed multiple myeloma patients will live more than 4 years.  The 2015 American Society of Hematology (ASH) Annual Meeting highlighted how recent drug approvals are driving a significant change in the treatment and survival landscape for these patients.  Three drugs alone were approved in November of 2015 (daratumumab - Darzalex, elotuzumab - Empliciti, and ixazomib - Nilaro), in addition to 4 others for the year.

For more information, go to:

http://www.ascopost.com/issues/january-25,-2016/multiple-myeloma-in-2015-a-year-for-the-record-books.aspx

 


 


 

How can we help?

Information for physicians and medical staff

Get more info

New & Known

What’s happening in oncology

Learn more

We’re hiring!

Be a part of helping us to save lives

Start helping today
Billing questions?